ADEPT antibody

1
(No Transcript)
2
01
Introduction
Content
02
ADEPT System
3
PART 01
Introduction
As a targeted therapy strategy, ADEPT is a
historical approach to achieve selective tumor
cell elimination.
4

Introduction
It is well-known that the efficacy of cytotoxic
chemotherapy for cancer is limited due to its
effects on regular tissues. Confining the action
of cytotoxic substances to cancer sites can
significantly reduce systemic toxicity, thereby
increase drug efficacy. ADEPT antibody, first
presented and tested by Bagshawe et al, was
designed for this very purpose and it contribute
to limiting the action of cytotoxic substances to
the cancer sites via (1) to produce the
cytotoxic substances exclusively at the cancer
sites and (2) to retain the cytotoxic substances
at cancer sites. ADEPT creates high cytotoxic
agent concentrations directly inside or around a
tumor cell, therefore decreasing the collateral
toxicity related to normal tissue exposure.

5
PART 02
ADEPT System
ADEPT is regarded as an indirect targeting
method that involves two steps.
6

ADEPT System
Firstly, a non-toxic antibodyenzyme fusion
protein is applied to the tumor matrix and binds
to the tumor cells via tumor-specific antigen
recognized by the antibody. Upon binding, an
inert small-molecule prodrug is then given. The
prodrug is the substrate for the enzyme portion
of the antibodyenzyme fusion that is anchored to
the tumor surface. Once the prodrug reaches the
enzyme, an active cytotoxic agent is produced by
the enzyme and cause cancer cell death. Comparing
to conventional ADCs or other antibody targeted
drugs, the actual effector molecule in ADEPT is
generated upon the application and conversion of
the prodrug, while the enzyme that attaches to
the antibody is essentially non-toxic.

7
(No Transcript)
8
Reference https//www.creative-biolabs.com/adc/to
xic-enzymes-adept.htm